WallStSmart

Atossa Genetics Inc (ATOS)vsVertex Pharmaceuticals Inc (VRTX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

VRTX leads profitability with a 30.7% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 58/100 (C).

ATOS

Avoid

26

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 4.8
Piotroski: 1/9Altman Z: -5.86

VRTX

Buy

58

out of 100

Grade: C

Growth: 5.3Profit: 9.0Value: 6.0Quality: 8.0
Piotroski: 4/9Altman Z: 3.69
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ATOS.

VRTXUndervalued (+46.6%)

Margin of Safety

+46.6%

Fair Value

$974.60

Current Price

$515.02

$459.58 discount

UndervaluedFair: $974.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ATOS1 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

VRTX4 strengths · Avg: 9.8/10
Profit MarginProfitability
30.7%10/10

Keeps 31 of every $100 in revenue as profit

Operating MarginProfitability
37.8%10/10

Strong operational efficiency at 37.8%

Altman Z-ScoreHealth
3.6910/10

Safe zone — low bankruptcy risk

Market CapQuality
$137.57B9/10

Large-cap with strong market position

Areas to Watch

ATOS4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$19.56M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

VRTX3 concerns · Avg: 3.3/10
PEG RatioValuation
2.384/10

Expensive relative to growth rate

P/E RatioValuation
34.9x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-39.0%2/10

Earnings declined 39.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : ATOS

The strongest argument for ATOS centers on Price/Book.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 30.7% and operating margin at 37.8%. Revenue growth of 11.8% demonstrates continued momentum.

Bear Case : ATOS

The primary concerns for ATOS are Revenue Growth, EPS Growth, Market Cap.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, EPS Growth.

Key Dynamics to Monitor

ATOS profiles as a value stock while VRTX is a mature play — different risk/reward profiles.

ATOS carries more volatility with a beta of 1.37 — expect wider price swings.

VRTX is growing revenue faster at 11.8% — sustainability is the question.

VRTX generates stronger free cash flow (546M), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (58/100 vs 26/100), backed by strong 30.7% margins and 11.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Atossa Genetics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs in the areas of oncology and infectious diseases. The company is headquartered in Seattle, Washington.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?